Amiodarone and thyroid status in refractory arrhythmias.

Out of 20 subjects selected for refractory arrhythmias, amiodarone therapy (200 mg/day) was efficacious in 85%. No statistically significant variations in electrocardiographic parameters (QTc) were observed; similarly, there was little evidence of side effects 1 year after initiation of treatment. These results were most likely due to the low daily dosage administered. We observed: 1) a significant increase in rT3 levels; 2) a decrease in TT3; 3) a uniform homeostasis of free fraction (FT3;FT4) These effects are all characteristic patterns of a "Low T3 Syndrome". The dosage of circulating amiodarone in 6 patients with borderline hormonal status (3 hyper- and 3 hypothyroidism) was not found to be an efficacious test for therapeutic monitoring. Identification of a statistically significant linear regression relationship between cumulative dose of amiodarone and rT3 levels may be a useful test in clinical practise for establishing more appropriate therapeutic dosages. Furthermore, it provides a guideline for threshold levels (maximum rT3 = 100-110 ng/dl) which are in close association with several side effects.

A multicentre comparison of flurbiprofen and naproxen in rheumatoid arthritis: a four-week study in 118 patients.

One-hundred and eighteen patients with rheumatoid arthritis were treated for 4 weeks with flurbiprofen 300 mg/day (sixty patients) or naproxen 750 mg/day (fifty-eight patients) in a six-centre randomized trial. Flurbiprofen proved to be more effective than naproxen in reducing morning stiffness (p less than 0.01), Ritchie articular index (p less than 0.01) and number of swollen joints (p less than 0.05) and in relieving night pain (p less than 0.01). The incidence and severity of side-effects, mainly gastric, were both low and similar with flurbiprofen (17%) and naproxen (19%).

Controlled multicenter trial of tiopronin and d-penicillamine for rheumatoid arthritis.

Fifty-seven patients took part in a controlled double-blind trial between tiopronin and D-penicillamine as basic treatment for rheumatoid arthritis. Thirty-nine (19 receiving tiopronin, 20 receiving D-penicillamine) completed the trial after 1 year. Both drugs resulted in a decrease of the erythrocyte sedimentation rate, Ritchie index, and Lee index and in a sparing effect on symptomatic antiinflammatory therapy. Improvement in these variables was statistically highly significant at any interval with tiopronin, but was sometimes less or not at all significant with D-penicillamine. Nevertheless, the difference in effects between the 2 drugs never reached statistical significance. Six patients receiving tiopronin and 6 receiving D-penicillamine were taken out of the experiment because of side effects.

Leukocyte migration and phagocytosis in progressive systemic sclerosis.

Experiments "in vitro" have been performed to study the chemotactic and phagocytotic response of PMN in 9 patients suffering from progressive systemic sclerosis (PSS). Their granulocytes showed a normal behaviour in all of these functions, when compared with healthy volunteers as controls.

[Amyotrophic lateral pseudosclerosis in the course of rheumatoid disease. Report of a case]. / Pseudosclerosi laterale amiotrofica in corso di malattia reumatoide. Segnalazione di un caso.

The Authors describe a case of amyotrophic lateral pseudosclerosis observed in the course of rheumatoid arthritis. They also discuss the pathogenesis of the neurological complication suggesting the possibility of a progressive myelopathy of vascular origin with arteriosclerotic and vasculitic component.

[Tiopronine: new basic treatment for rheumatoid arthritis. Open study of 158 cases]. / La tiopronine, nouveau traitement de fond de la polyarthrite rhumatoïde. Etude ouverte de 158 cas.

A study of patients with rheumatoid arthritis permitted us to note the interest of tiopronine (sulfhydryl compound of the d-penicillamine type) in the basic treatment of rheumatoid arthritis. The dose of the drug was on average, 1 gram daily, which, in one series of patients, was administered at the start of treatment and in another series, with an increase of dosage of 250 mg every 20 days. The results, judged by the reduction of the Ritchie and Lee index, of the E.R.S. and the steroid and non-steroid anti-inflammatory requirements, are good (very good and good) in 47% of cases. These patients were in an advanced stage of the disease and there had been numerous therapeutic failures. Side effects similar to those observed during treatment with D-penicillamine were present in 38% of cases, and in 31% required stopping treatment. It is likely that the frequency of stopping treatment for side effects was definitely exaggerated. The place of this new drug in the basic treatment of rheumatoid arthritis requires further study by a double blind test with D-penicillamine, and this is at present in progress.

[Pyrasanone in the treatment of rheumatism]. / Il pyrasanone nella terapia antireumatica

The results of a set of experiments conducted on a new non-steroid antirheumatic preparation--pyrasanone (Carudol)--are presented and its indications in the general management of the disease are noted. The pharmacokinetics and therapeutic efficacy of the new drug are described. Statistical analysis showed it to be more effective than hexahydropyrazine, diphenylbutazone, indomethacin and oxyphenbutazone. A basic therapeutic approach is suggested in accordance with the pharmacodynamic aspects of the drug and the results observed in a clinical trial on 719 subjects. Pyrasanone has low toxicity and is well tolerated. Due caution in the administration of antirheumatic drugs should nevertheless be maintained during its use.